테고사이언스
Financials
Valuation Metrics
테고사이언스's Market Cap is ₩605B. At end of 2025 it was ₩1322B. Ranked #1651 of 2,421 in KR market (top 68%), #986 of 1,640 on KOSDAQ (top 60%), #179 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 77%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 60.49B KRW | KR#1,651/2,421 Sec#179/231 |
| Revenue | 6.18B KRW | KR#2,322/2,421 Sec#187/231 |
| Net Income | -12.92B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 76.38B KRW | KR#1,960/2,421 Sec#161/231 |
| Net Assets | 43.60B KRW | KR#1,997/2,421 Sec#173/231 |
| Employees | 39 | KR#2,139/2,421 Sec#197/231 |
| Value | ||
| P/B | 1.39x | KR#1,724/2,421 Sec#118/231 |
| P/S | 9.79x | KR#2,277/2,421 Sec#165/231 |
| FCF Yield | -5.15% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -29.64% | KR#2,179/2,421 Sec#173/231 |
| ROA | -16.92% | KR#2,214/2,421 Sec#171/231 |
| Op. Margin | -98.57% | KR#2,300/2,421 Sec#172/231 |
| Revenue Growth | -5.15% | KR#1,775/2,421 Sec#169/231 |
| Financial Health | ||
| Debt Ratio | 75.19% | KR#1,281/2,421 Sec#153/231 |
| Total Debt | 2.40B KRW | KR#1,887/2,421 Sec#184/231 |
| FCF | -3.12B KRW | KR#1,397/2,421 Sec#108/231 |
| Cash | 5.69B KRW | KR#1,963/2,421 Sec#178/231 |
| Current Ratio | 1.64x | KR#1,087/2,421 Sec#121/231 |
| Performance | ||
| 1Y Return | -58.99% | KR#2,190/2,421 Sec#207/231 |
| 1M Return | -7.79% | KR#1,987/2,421 Sec#164/231 |
| From 52W High | -61.49% | KR#1,908/2,421 Sec#151/231 |
| 1Y MDD | -70.48% | KR#2,011/2,421 Sec#175/231 |
| Trading | ||
| Volume | 3,255 shares | KR#2,213/2,421 Sec#209/231 |
| Trading Value | 24.2M KRW | KR#2,100/2,421 Sec#210/231 |
| Foreign Own. | 1.61% | KR#1,788/2,421 Sec#174/231 |
| Per Share | ||
| EPS | -1,593 KRW | KR—/2,421 Sec—/231 |
| BPS | 5,376 KRW | KR#1,441/2,421 Sec#102/231 |
Company Info
Tegosciece, established in 2001 and listed on KOSDAQ in 2014, specializes in the development, manufacturing, and sale of cell therapy products. Utilizing world-class cell culture technology, the company is a leader, holding three of 16 approved cell therapy products (Holoderm, Caloderm, Rosmir). Initially developing wound healing cell therapy products for burns and foot ulcers, Tegosciece is now expanding into regenerative medicine new drug development for musculoskeletal diseases, including domestic and U.S. clinical trials for rotator cuff tear treatment. It is headquartered in Gangseo-gu, Seoul.